The invention is directed to a pharmaceutical composition comprising a progesterone receptor antagonist namely (11β,17β)-17-Hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one at the dosage of about 0.5 to 5 mg and more particularly 2 mg. Additionally, the invention is directed to the use of the novel pharmaceutical composition for treatment of and/or prophylaxis of gynaecological diseases, such as fibroids of the uterus (myomas, uterine leiomyoma), endometriosis or excessive menstrual bleeds, and method for obtaining such composition and oral dosage form.本發明係關於一種醫藥組合物，其包含劑量約0.5 mg至5 mg，且更特定言之2 mg之黃體激素受體拮抗劑，亦即(11β,17β)-17-羥基-11-[4-(甲基磺醯基)苯基]-17-(五氟乙基)雌甾-4,9-二烯-3-酮。另外，本發明係關於該新穎醫藥組合物用於治療及/或預防婦科疾病(諸如：子宮之類纖維瘤(肌瘤、子宮平滑肌瘤)、子宮內膜異位或月經出血過量)之用途，及獲得該組合物及口服劑型之方法。
